Disclosed are bioavailable solid state (17-β)-3-Oxoandrost-4-en-17-yl dodecanoate compositions and methods of use in administration to mammals in need of thereof. The (17-β)-3-Oxoandrost-4-en-17-yl dodecanoate is preferably provided in a solid state crystalline form having a plurality of peaks corresponding to the peaks shown in FIG. 2, a plurality of crystallites ranging in size from about 40 nm to about 60 nm based as identified via powder x-ray diffraction spectra, and a melting point in the range of about 51° C. to about 63° C. The compositions may be provided in oral or injectable administration form for the treatment of conditions such as in need of testosterone therapy. An exemplary chemical structure of a (17-β)-3-Oxoandrost-4-en-17-yl dodecanoate composition disclosed herein is as follows:
本发明公开了
生物可利用的固态(17-β)-3-氧代
雄甾烷-4-烯-17-基
十二烷酸酯组合物和用于给需要的哺乳动物用药的方法。(17-β)-3-氧代
雄甾烷-4-烯-17-基
十二烷酸酯优选以固态结晶形式提供,其具有与图 2 中所示峰值相对应的多个峰值,通过粉末 X 射线衍射光谱确定的多个结晶尺寸范围为约 40 纳米至约 60 纳米,熔点范围为约 51 摄氏度至约 63 摄氏度。本文公开的(17-β)-3-氧代
雄甾烷-4-烯-17-基
十二烷酸酯组合物的示例性
化学结构如下: